AU2013311573B2 - Methods of treating Alzheimer's disease and pharmaceutical compositions thereof - Google Patents

Methods of treating Alzheimer's disease and pharmaceutical compositions thereof Download PDF

Info

Publication number
AU2013311573B2
AU2013311573B2 AU2013311573A AU2013311573A AU2013311573B2 AU 2013311573 B2 AU2013311573 B2 AU 2013311573B2 AU 2013311573 A AU2013311573 A AU 2013311573A AU 2013311573 A AU2013311573 A AU 2013311573A AU 2013311573 B2 AU2013311573 B2 AU 2013311573B2
Authority
AU
Australia
Prior art keywords
dose
indol
ethyl
compound
benzylamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013311573A
Other languages
English (en)
Other versions
AU2013311573A1 (en
AU2013311573A8 (en
Inventor
Johan AREBERG
Ellen Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013311573(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2013311573A1 publication Critical patent/AU2013311573A1/en
Publication of AU2013311573A8 publication Critical patent/AU2013311573A8/en
Application granted granted Critical
Publication of AU2013311573B2 publication Critical patent/AU2013311573B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013311573A 2012-09-09 2013-09-06 Methods of treating Alzheimer's disease and pharmaceutical compositions thereof Active AU2013311573B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US61/698,664 2012-09-09
US201361782084P 2013-03-14 2013-03-14
US61/782,084 2013-03-14
PCT/EP2013/068516 WO2014037532A1 (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Publications (3)

Publication Number Publication Date
AU2013311573A1 AU2013311573A1 (en) 2015-03-12
AU2013311573A8 AU2013311573A8 (en) 2015-03-19
AU2013311573B2 true AU2013311573B2 (en) 2017-10-12

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013311573A Active AU2013311573B2 (en) 2012-09-09 2013-09-06 Methods of treating Alzheimer's disease and pharmaceutical compositions thereof

Country Status (33)

Country Link
US (4) US9375418B2 (https=)
EP (1) EP2892563B1 (https=)
JP (2) JP6693744B2 (https=)
KR (2) KR102342127B1 (https=)
CN (1) CN104619344A (https=)
AP (1) AP2015008306A0 (https=)
AU (1) AU2013311573B2 (https=)
BR (1) BR112015005117B1 (https=)
CA (1) CA2883751C (https=)
CL (1) CL2015000578A1 (https=)
CY (1) CY1121062T1 (https=)
DK (1) DK2892563T3 (https=)
EA (1) EA030448B1 (https=)
ES (1) ES2703630T3 (https=)
GE (1) GEP201706776B (https=)
HR (1) HRP20182069T1 (https=)
IL (1) IL237369B (https=)
JO (1) JO3459B1 (https=)
LT (1) LT2892563T (https=)
MX (1) MX368305B (https=)
MY (1) MY182539A (https=)
NI (1) NI201500031A (https=)
NZ (1) NZ630589A (https=)
PL (1) PL2892563T3 (https=)
PT (1) PT2892563T (https=)
RS (1) RS58104B1 (https=)
RU (1) RU2675786C2 (https=)
SG (1) SG11201501774QA (https=)
SI (1) SI2892563T1 (https=)
SM (1) SMT201800678T1 (https=)
TN (1) TN2015000076A1 (https=)
TW (1) TWI632909B (https=)
WO (1) WO2014037532A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2845473T3 (es) 2013-03-14 2021-07-26 Boehringer Ingelheim Int (Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
JO3639B1 (ar) 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
EP3511331A1 (en) 2014-09-12 2019-07-17 Boehringer Ingelheim International GmbH Spirocyclic inhibitors of cathepsin c
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
JP2018515607A (ja) * 2015-05-07 2018-06-14 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 神経変性疾患を処置する組成物および方法
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
US10383849B2 (en) * 2016-04-26 2019-08-20 H. Lundbeck A/S Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in Parkinson's disease patients
US10864191B2 (en) 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
EA036347B1 (ru) 2016-05-18 2020-10-29 Сувен Лайф Сайенсиз Лимитед Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
BR112019001145A2 (pt) * 2017-05-24 2019-04-30 H. Lundbeck A/S combinação de um antagonista do receptor 5-ht6 e de um inibidor de acetilcolinesterase para uso no tratamento da doença de alzheimer em uma subpopulação de pacientes portadores de alelos de apoe4
MY205440A (en) 2018-09-28 2024-10-21 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069079A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
JP7697934B2 (ja) 2019-09-30 2025-06-24 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase
EP3960174B1 (en) 2020-08-28 2024-10-30 Westfälische Wilhelms-Universität Münster Parasympathetic active phenyl-glycosid-substituted hydroxy-methyl-piperidine and -pyrrolidine alkaloids for medicinal use
WO2025198622A1 (en) * 2024-03-22 2025-09-25 Queen Aaric Magnesium and lidocaine composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044090B2 (en) * 2001-03-29 2011-10-25 Eli Lilly N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
DE69411143T2 (de) 1993-09-01 1998-10-22 Allelix Biopharma Tryptamin analoge mit 5-ht1d selektivität
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
AU752008B2 (en) 1997-09-29 2002-09-05 Aventis Pharmaceuticals Inc. Aminoalkylphenol derivatives and related compounds
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
CA2353962C (en) 1998-12-11 2009-09-29 Virginia Commonwealth University Selective 5-ht6 receptor ligands
CZ20012502A3 (cs) 1999-01-13 2002-03-13 Millennium Pharmaceuticals, Inc. Funkcionalizované heterocykly jako modulátory chemokinových receptorů
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
RU2252936C2 (ru) 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
JP2009541423A (ja) 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US20120184532A1 (en) * 2009-07-23 2012-07-19 Shire Llc Galantamine amino acid and peptide prodrugs and uses thereof
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044090B2 (en) * 2001-03-29 2011-10-25 Eli Lilly N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. LUNDBECK A/S: "Lundbeck’s Lu AE58054 meets primary endpoint in large placebo-controlled clinical proof of concept study in people with Alzheimer’s disease", H. LUNDBECK A/S CORPORATE RELEASE NO 472, 29 May 2012 (2012-05-29), XP055086588, Retrieved from the Internet <URL:http://files.shareholder.com/downloads/AMDA-GGC00/2770646123x0x572261/56d44979-8816-44e7-88ee-d9efd1e4a634/Release no 472.pdf> [retrieved on 20131104] *

Also Published As

Publication number Publication date
BR112015005117A2 (pt) 2017-07-04
IL237369B (en) 2018-11-29
SG11201501774QA (en) 2015-05-28
MX2015002879A (es) 2015-07-06
CA2883751A1 (en) 2014-03-13
US20160256437A1 (en) 2016-09-08
BR112015005117B1 (pt) 2022-06-21
WO2014037532A1 (en) 2014-03-13
AU2013311573A1 (en) 2015-03-12
RU2675786C2 (ru) 2018-12-25
TW201414474A (zh) 2014-04-16
US10660878B2 (en) 2020-05-26
CY1121062T1 (el) 2019-12-11
TN2015000076A1 (en) 2016-06-29
KR20150065680A (ko) 2015-06-15
US20180071254A1 (en) 2018-03-15
DK2892563T3 (en) 2019-01-21
RS58104B1 (sr) 2019-02-28
SI2892563T1 (sl) 2019-02-28
NI201500031A (es) 2016-02-15
JP2019059760A (ja) 2019-04-18
CA2883751C (en) 2020-11-24
US9687473B2 (en) 2017-06-27
JP6693744B2 (ja) 2020-05-13
AU2013311573A8 (en) 2015-03-19
HK1212217A1 (en) 2016-06-10
AP2015008306A0 (en) 2015-03-31
LT2892563T (lt) 2019-01-10
EP2892563B1 (en) 2018-11-14
MY182539A (en) 2021-01-25
CL2015000578A1 (es) 2015-05-15
US20160354343A1 (en) 2016-12-08
KR102342127B1 (ko) 2021-12-21
NZ630589A (en) 2015-12-24
KR20200137028A (ko) 2020-12-08
US9375418B2 (en) 2016-06-28
IL237369A0 (en) 2015-04-30
EA201590353A1 (ru) 2016-03-31
EA030448B1 (ru) 2018-08-31
US9789085B2 (en) 2017-10-17
RU2015107877A (ru) 2016-10-27
MX368305B (es) 2019-09-27
JO3459B1 (ar) 2020-07-05
GEP201706776B (en) 2017-11-27
HRP20182069T1 (hr) 2019-02-08
CN104619344A (zh) 2015-05-13
PL2892563T3 (pl) 2019-04-30
PT2892563T (pt) 2019-01-10
SMT201800678T1 (it) 2019-02-28
TWI632909B (zh) 2018-08-21
EP2892563A1 (en) 2015-07-15
US20140073681A1 (en) 2014-03-13
JP2015528471A (ja) 2015-09-28
ES2703630T3 (es) 2019-03-11

Similar Documents

Publication Publication Date Title
AU2013311573B2 (en) Methods of treating Alzheimer&#39;s disease and pharmaceutical compositions thereof
CA2943598C (en) S1p modulator immediate release dosage regimen
US12161758B2 (en) Modified release formulations and uses thereof
Zimmermann et al. The pharmacokinetics of extended‐release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times
HK1212217B (en) Pharmaceutical compositions for treating alzheimer&#39;s disease
OA17281A (en) Methods of treating alzheimer&#39;s disease and pharmaceutical compositions thereof.
TW202322816A (zh) 篩選 vmat2 抑制劑之方法
US8377979B2 (en) Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
WO2007030589A2 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
TW202237084A (zh) 修飾釋放調配物及其用途
HK40081576A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases
HK40053433A (en) Siponimod immediate release dosage regimen for treating autoimmune diseases

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 9 , PAGE(S) 1439 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME H. LUNDBECK A/S, APPLICATION NO. 2013311573, UNDER INID (54) CORRECT THE TITLE TO READ METHODS OF TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS THEREOF

FGA Letters patent sealed or granted (standard patent)